Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

As part of a combined antiretroviral regimen, doravirine is safe and effective at suppressing viral replication in both treatment-naive and treatment-experienced adults living with human immunodeficiency virus (HIV)-1 who have no history of drug resistance against doravirine. In virologically suppre...

Full description

Bibliographic Details
Main Authors: Hanh Thi Pham, Meng A Xiao, Miguel AV Principe, Alexander Wong, Thibault Mesplède
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-03-01
Series:Drugs in Context
Subjects:
antiretroviral therapy
doravirine
drug resistance
highly active
hiv
reverse transcriptase inhibitors
Online Access:https://www.drugsincontext.com/pharmaceutical,-clinical,-and-resistance-information-on-doravirine,-a-novel-non-nucleoside-reverse-transcriptase-inhibitor-for-the-treatment-of-hiv-1-infection/

Internet

https://www.drugsincontext.com/pharmaceutical,-clinical,-and-resistance-information-on-doravirine,-a-novel-non-nucleoside-reverse-transcriptase-inhibitor-for-the-treatment-of-hiv-1-infection/

Similar Items